Harvard Bioscience (HBIO) Total Debt (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Debt data on file, last reported at $36.2 million in Q1 2026.

• On a quarterly basis, Total Debt rose 0.7% year-over-year to $36.2 million in Q1 2026; TTM through Mar 2026 was $36.2 million, a 0.7% increase from a year earlier, with the FY2025 full-year figure at $35.9 million, down 2.94% from the prior year.
• Total Debt for Q1 2026 stood at $36.2 million, up from $35.9 million in the prior quarter.
• Over the last five years, Total Debt for HBIO reached as high as $51.7 million in Q1 2022 and fell as low as $34.0 million in Q3 2025.
• Historically, Total Debt has averaged $41.1 million across 5 years, with a median of $38.7 million in 2023.
• Across the five-year window, Total Debt climbed 18.62% in 2022 and declined 24.27% in 2024, its largest moves.
• Year by year, Total Debt stood at $46.8 million in 2022, then declined by 9.4% to $42.4 million in 2023, then dropped by 12.88% to $37.0 million in 2024, then slipped by 2.94% to $35.9 million in 2025, then climbed by 0.95% to $36.2 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $36.2 million in Q1 2026, $35.9 million in Q4 2025, and $34.0 million in Q3 2025.